scholarly journals Clinical Features of Intra-Abdominal Abscess and Intestinal Free-Wall Perforation in Korean Patients with Crohn’s Disease: Results from the CONNECT Study

2020 ◽  
Vol 10 (1) ◽  
pp. 116
Author(s):  
Seok-Hoo Jeong ◽  
Ja Sung Choi ◽  
Jin Woo Kim ◽  
Hee Man Kim ◽  
Hyun-Soo Kim ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Features ◽  
Common Mechanism ◽  
Abdominal Abscess ◽  
Free Wall ◽  
Korean Patients ◽  
Increased Risk ◽  
Wall Perforation

Background: In Crohn’s disease (CD), intra-abdominal abscess (IA) and intestinal free-wall perforation (IP) have a common mechanism of transmural inflammation; however, their manifestation is different. Objective: This study aimed to investigate differences in the clinical features between IA and IP in Korean patients with Crohn’s disease. Design: A retrospective cohort study. Setting: Thirty university hospitals and two local hospitals in Korea. Patients: Patients who were diagnosed with CD between July 1982 and December 2008 were enrolled. Main Outcome Measures: Clinical characteristics of IA and IP. Results: Among 1286 patients with CD, 147 (11.4%) had IA and 83 (6.5%) had IP. IA patients were younger than those of IP (24.2 ± 8.6 vs. 30.4 ± 11.1 years, p = 0.001). Location and behavior were significantly different between IA and IP (p = 0.035 and 0.021). In multivariate analyses, perianal fistula was not associated with increased risk of IA and IP, while intestinal stricture was associated with increased risk of IA (OR: 2.72, p < 0.0001) and IP (OR: 2.76, p < 0.0001). In subgroup analyses, 55 (36.5%) IA patients were diagnosed at the diagnosis of CD, and 92 (63.5%) during follow-up of CD, while 47 (56.6%) IP patients were diagnosed at the diagnosis of CD, and 36 (43.3%) during follow-up of CD. Conclusions: There are several differences in the clinical features of IA and IP in Korean patients with CD. The development mechanism is considered as identical, but further investigation should be needed for clinical implication.

The Incidence of Deep Venous Thrombosis and Pulmonary Embolism among Patients with Inflammatory Bowel Disease: A Population-based Cohort Study

2001 ◽  
Vol 85 (03) ◽  
pp. 430-434 ◽  
Author(s):  
James Blanchard ◽  
Donald Houston ◽  
Andre Wajda ◽  
Charles Bernstein
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Pulmonary Embolism ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Population Based ◽  
Incidence Rates ◽  
Increased Risk ◽  
Inflammatory Bowel

Summary Background: There is an impression mostly from specialty clinics that patients with inflammatory bowel disease (IBD) have an increased risk of venous thromboembolic disorders. Our aim was to determine the incidence of deep venous thrombosis (DVT) and pulmonary embolism (PE) from a population-based database of IBD patients and, to compare the incidence rates to that of an age, gender and geographically matched population control group. Methods: IBD patients identified from the administrative claims data of the universal provincial insurance plan of Manitoba were matched 1:10 to randomly selected members of the general population without IBD by year, age, gender, and postal area of residence using Manitoba Health’s population registry. The incidence of hospitalization for DVT and PE was calculated from hospital discharge abstracts using ICD-9-CM codes 451.1, 453.x for DVT and 415.1x for PE. Rates were calculated based on person-years of follow-up for 1984-1997. Comparisons to the population cohort yielded age-adjusted incidence rate ratios (IRR). Rates were calculated based on person-years of follow-up (Crohn’s disease = 21,340, ulcerative colitis = 19,665) for 1984-1997. Results: In Crohn’s disease the incidence rate of DVT was 31.4/10,000 person-years and of PE was 10.3/10,000 person-years. In ulcerative colitis the incidence rates were 30.0/10,000 person-years for DVT and 19.8/10,000 person-years for PE. The IRR was 4.7 (95% CI, 3.5-6.3) for DVT and 2.9 (1.8-4.7) for PE in Crohn’s disease and 2.8 (2.1-3.7) for DVT and 3.6 (2.5-5.2) for PE, in ulcerative colitis. There were no gender differences for IRR. The highest rates of DVT and PE were seen among patients over 60 years old; however the highest IRR for these events were among patients less than 40 years. Conclusion: IBD patients have a threefold increased risk of developing DVT or PE.

Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014

Gut ◽  
2019 ◽  
Vol 69 (3) ◽  
pp. 453-461 ◽  
Author(s):  
Ola Olén ◽  
Johan Askling ◽  
Michael C Sachs ◽  
Martin Neovius ◽  
Karin E Smedby ◽  
...  
Keyword(s):  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Adult Onset ◽  
Risk Of Death ◽  
Increased Risk ◽  
Elderly Onset ◽  
Incident Cases ◽  
Over Time

ObjectivesTo examine all-cause and cause-specific mortality in adult-onset and elderly-onset IBD and to describe time trends in mortality over the past 50 years.DesignSwedish nationwide register-based cohort study 1964–2014, comparing mortality in 82 718 incident IBD cases (inpatient and non-primary outpatient care) with 10 times as many matched general population reference individuals (n=801 180) using multivariable Cox regression to estimate HRs. Among patients with IBD, the number of participants with elderly-onset (≥60 years) IBD was 17 873.ResultsDuring 984 330 person-years of follow-up, 15 698/82 718 (19%) of all patients with IBD died (15.9/1000 person-years) compared with 121 095/801 180 (15.1%) of reference individuals, corresponding to an HR of 1.5 for IBD (95% CI=1.5 to 1.5 (HR=1.5; 95% CI=1.5 to 1.5 in elderly-onset IBD)) or one extra death each year per 263 patients. Mortality was increased specifically for UC (HR=1.4; 95% CI=1.4 to 1.5), Crohn’s disease (HR=1.6; 95% CI=1.6 to 1.7) and IBD-unclasssified (HR=1.6; 95% CI=1.5 to 1.8). IBD was linked to increased rates of multiple causes of death, including cardiovascular disease (HR=1.3; 1.3 to 1.3), malignancy (HR=1.4; 1.4 to 1.5) and digestive disease (HR=5.2; 95% CI=4.9 to 5.5). Relative mortality during the first 5 years of follow-up decreased significantly over time. Incident cases of 2002–2014 had 2.3 years shorter mean estimated life span than matched comparators.ConclusionsAdult-onset and elderly-onset patients with UC, Crohn’s disease and IBD-unclassified were all at increased risk of death. The increased mortality remained also after the introduction of biological therapies but has decreased over time.

scholarly journals P510 Postoperative enterocoutaneous fistula after surgery for Crohn’s disease performed in a tertiary centre over 15 years: analysis of the long-term outcomes and predictors of fistula closure

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S490-S491
Author(s):  
D Parlanti1 ◽  
G Poggioli ◽  
S Cardelli ◽  
M Tanzanu ◽  
L Boschi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Median Time ◽  
Intestinal Failure ◽  
Chi Square ◽  
Tertiary Centre ◽  
Kaplan Meier ◽  
Increased Risk

Abstract Background Patients with Crohn’s disease (CD) have an increased risk to develop enterocoutaneous fistula (ECF) after surgery. Although conservative therapy could be advisable, in some cases surgery is unavoidable, despite there might be greater risks of intestinal failure associated with redo surgery. Methods CD patients affected by postoperative ECF (within 90 days from surgery) between 2004 and 2020, and followed for at least 3 months after the onset of the ECF, were retrospectively included. Variables were presented as median (range) or number (%).Chi-square, Fisher’s exact and Wilcoxon rank sum tests were used as appropriate. The Kaplan-Meier method was performed to analyse the rate of ECF closure over the follow-up time, and to compare the outcome between subgroups of patients. Results Eighteen patients were included in the study. The perioperative variables are reported in Figure 1. The median follow-up time was 29.5 months (range 0–204), and the median time to ECF closure was 104 days (24–954), although a clinical remission (defined as an ECG non requiring hospitalization) was obtained after a median time of 41 days (15–768). The comparison of the rates of ECF closure between subgroups of patients over the follow-up are reported in Figure 2 and 3. Conclusion The ECF output is the only variable which is significantly associated with the rate of ECF closure. The origin of ECF from an ileo-colic or a colo-colic anastomosis seems to be associated with a faster progression towards fistula healing as compared to an origin from the small bowel (ECF closure at 3 and 6 months: 56.3% vs 22.2% and 70.8% vs 33.3%, respectively; p=0.19). The use of NPWT and, when feasible, an early surgical treatment, might increase the chance of ECF closure within 3 months (55.5% vs 12.5%, p=0.43 and 66.7% vs 29.9%, p=0.32, respectively). Although postoperative ECF represents a challenging complication in CD, the present study shows that a complete closure is obtainable in the long-term in all patients treated in a referral centre.

scholarly journals Clinical features of Crohn's disease in Korean patients residing in Busan and Gyeongnam

2016 ◽  
Vol 14 (1) ◽  
pp. 30 ◽  
Author(s):  
Eun Ji Lee ◽  
Tae Oh Kim ◽  
Geun Am Song ◽  
Jong hun Lee ◽  
Hyung Wook Kim ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Clinical Features ◽  
Korean Patients

scholarly journals OP14 Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn’s disease: A Scandinavian population-based cohort study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S013-S014
Author(s):  
O Olen ◽  
R Erichsen ◽  
M C Sachs ◽  
L Pedersen ◽  
J Halfvarson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cohort Study ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
General Population ◽  
Cox Regression ◽  
Population Based ◽  
Tumour Stage ◽  
Increased Risk

Abstract Background Crohn’s disease (CD) is a risk factor for colorectal cancer (CRC). Earlier studies reflect older treatment and surveillance strategies, and most have studied incident CRC without addressing potential lead-time and surveillance biases. Such bias can be reduced by examining tumour stage-adjusted CRC incidence and CRC mortality. We aimed to assess risks of CRC mortality and incident CRC among patients with CD compared with the general population. Methods Nationwide register-based cohort study during 1969–2017 of 47,035 patients with CD in Denmark (n = 13,056) and Sweden (n = 33,979), compared with 463,187 general population reference individuals, matched for sex, age, calendar year, and place of residence. We used Cox regression to estimate hazard ratios (HRs) for incident CRC and CRC mortality. In a multistate model, assessing competing events during follow-up (CRC diagnosis, CRC death, other death), we also took a tumour stage into account. Results During 1969–2017, 499 patients with CD developed CRC, corresponding to an adjusted HR of 1.40 [95% confidence interval (CI) 1.27–1.53]. We observed 296 (0.47/1000 person-years) deaths from CRC in patients with CD compared with 1968 (0.31/1000) in reference individuals [HR 1.74 (95% CI 1.54–1.96)]. CD patients diagnosed with CRC were at increased risk of CRC mortality compared with reference individuals also diagnosed with CRC [HR = 1.30 (95% CI 1.06–1.59)] and tumour stage at CRC diagnosis did not differ between groups (p = 0.27). CD patients who had 8 or more years of follow-up or who were diagnosed with primary sclerosing cholangitis (PSC) and hence were potentially eligible for CRC surveillance had an increased overall risk of CRC death [HR 1.41 (95% CI 1.18–1.69)] or CRC diagnosis [HR = 1.12 (95% CI = 0.98–1.28)]. However, in patients potentially eligible for CRC surveillance, we only found significantly increased risks in patients with CD onset &lt;40 years, disease activity in the colon only, or with PSC (Figure 1). Conclusion CD patients are at increased risk of a CRC diagnosis and CRC death. Despite repeated colonoscopies during follow-up, CD patients are not diagnosed earlier (less severe tumour stage) with CRC than reference individuals. Nevertheless, CD patients with CRC have higher mortality than non-CD patients also diagnosed with CRC. CRC surveillance could likely be improved and should be focussed on CD patients &lt;40 years at CD onset, patients with colon inflammation, and patients who have PSC.

scholarly journals Increased Risk of Liver Cirrhosis during Azathioprine Therapy for Crohn’s Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Jenny Roselli ◽  
Tommaso Innocenti ◽  
Erica Nicola Lynch ◽  
Laura Parisio ◽  
Giuseppe Macrì ◽  
...  
Keyword(s):  
Liver Cirrhosis ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Hepatic Cirrhosis ◽  
Transient Elastography ◽  
Azathioprine Therapy ◽  
Increased Risk ◽  
Penetrating Crohn’S Disease ◽  
Tomography Scan

Azathioprine is a cornerstone of the therapy of Crohn’s disease. Unfortunately, infections and malignancies are relatively common adverse effects related to this drug; however, cirrhosis is exceptionally reported as a side effect. We report the case of a 49-year-old male patient with ileocolonic steno-penetrating Crohn’s disease who developed hepatic cirrhosis while treated with azathioprine. After taking azathioprine for 3 years with regular follow-up, he developed pancytopenia, and liver cirrhosis was diagnosed with ultrasound, abdomen computed tomography scan, transient elastography, and liver biopsy. As all other causes of liver damage were excluded, azathioprine was believed to be the cause of liver injury and therefore was interrupted.

scholarly journals P239 Elderly-onset inflammatory bowel disease is associated with higher risks of infections, cancers and hospitalisation: Results from a territory-wide Hong Kong IBD registry

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S262-S264
Author(s):  
J W Y Mak ◽  
L T C Ho ◽  
K Wong ◽  
T Y Cheng ◽  
T C F Yip ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hong Kong ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Bowel Disease ◽  
Cancer Development ◽  
Increased Risk ◽  
Elderly Onset ◽  
Inflammatory Bowel

Abstract Background Incidence of elderly-onset inflammatory bowel disease (IBD), defined as age ≥ 60 at diagnosis, is increasing rapidly worldwide. We aimed to compare the clinical characteristics and natural history of elderly onset IBD patients to non-elderly onset IBD patients. Methods Patients with a confirmed diagnosis of IBD from 1981 to 2016 were identified from a territory-wide Hong Kong IBD registry involving 13 hospitals. Demographics, comorbidities, clinical features and outcomes of elderly-onset IBD patients were compared with non-elderly onset IBD patients. Results Total 2413 patients were identified, of whom 270 (11.2%) had elderly-onset IBD during 21805 person-years follow-up. Median follow-up duration was 111 months (Interquartile range [IQR]: 68–165 months). The ratio of ulcerative colitis (UC): Crohn’s disease (CD) was higher in elderly-onset IBD than non-elderly onset IBD patients. (3.82:1 vs. 1.39:1; p &lt; 0.001). Elderly-onset Crohn’s disease (CD) had less perianal involvement (5.4% vs. 25.4%; p &lt; .001) but more stricturing phenotype (32.1% vs. 20.5%; p = 0.04) than non-elderly onset. There was no difference in the rate of cumulative use of biologics (p = 0.49), but significantly lower use of immunosuppressants in elderly-onset IBD patients (p = 0.001). Cumulative risk of IBD-related surgeries was similar (p = 0.89). Elderly-onset IBD was associated with higher risks of cytomegalovirus colitis (Odds ratio [OR]: 3.07; 95% Confidence Interval (CI) 1.92–4.89; p &lt; 0.001); herpes zoster infections (OR: 2.42; 95% CI: 1.22–4.80; p = 0.12) and all cancer development (Hazard ratio: 2.97; 95% CI: 1.84–4.79; p &lt; 0.001). Elderly-onset IBD was also associated with increased number of overall hospitalisation (OR: 1.14; 95% CI 1.09–1.20; p &lt; 0.001), increased number of infections-related hospitalisation (OR: 1.87; 95% CI 1.47–2.38; p &lt; 0.001) and longer hospitalisation (OR: 1.004; 95% CI: 1.001- 1.007; p = 0.007) compared with non-elderly onset IBD. Conclusion Elderly-onset IBD has less perianal CD. However, they have significantly more comorbidities and are associated with increased risk of infections, cancer development and increased and prolonged hospitalisations. Specific therapeutic strategies are needed in this special group of patients.

scholarly journals Montreal classification of patient operated for Crohn's disease and identification of surgical recurrence predictors

2015 ◽  
Vol 42 (2) ◽  
pp. 97-104 ◽  
Author(s):  
Cristiane de Souza Bechara ◽  
Antonio Lacerda Filho ◽  
Maria de Lourdes Abreu Ferrari ◽  
Déborah Almeida Roquette Andrade ◽  
Magda Maria Profeta da Luz ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Retrospective Study ◽  
Surgical Treatment ◽  
Crohn's Disease ◽  
Median Time ◽  
Disease Recurrence ◽  
Surgical Recurrence ◽  
Increased Risk

OBJECTIVE: to evaluate Crohn's disease recurrence and its possible predictors in patients undergoing surgical treatment. METHODS: We conducted a retrospective study with Crohn's disease (CD) patients undergoing surgical treatment between January 1992 and January 2012, and regularly monitored at the Bowel Clinic of the Hospital das Clínicas of the UFMG. RESULTS: we evaluated 125 patients, 50.4% female, with a mean age of 46.12 years, the majority (63.2%) diagnosed between 17 and 40 years of age. The ileum was involved in 58.4%, whereas stenotic behavior was observed in 44.8%, and penetrating, in 45.6%. We observed perianal disease in 26.4% of cases. The follow-up average was 152.40 months. Surgical relapse occurred in 29.6%, with a median time of 68 months from the first operation. CONCLUSION: The ileocolic location, penetrating behavior and perianal involvement (L3B3p) were associated with increased risk of surgical recurrence.

scholarly journals Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease

2019 ◽  
Vol 12 (2) ◽  
pp. bcr-2018-225680 ◽  
Author(s):  
Talal Alzahrani ◽  
Abdulelah Nuqali ◽  
Nejat Naser ◽  
Amar R Jariwala
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Increased Risk ◽  
Binding Factor ◽  
Core Binding Factor Beta ◽  
Acute Myeloid

We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.

Sign in / Sign up

Export Citation Format

Share Document